HomeCompareDTCFF vs PLD

DTCFF vs PLD: Dividend Comparison 2026

DTCFF yields 500.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DTCFF wins by $61393.62M in total portfolio value
10 years
DTCFF
DTCFF
● Live price
500.00%
Share price
$0.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61399.52M
Annual income
$44,063,578,515.70
Full DTCFF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — DTCFF vs PLD

📍 DTCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDTCFFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DTCFF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DTCFF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DTCFF
Annual income on $10K today (after 15% tax)
$42,500.00/yr
After 10yr DRIP, annual income (after tax)
$37,454,041,738.34/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, DTCFF beats the other by $37,450,003,621.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DTCFF + PLD for your $10,000?

DTCFF: 50%PLD: 50%
100% PLD50/50100% DTCFF
Portfolio after 10yr
$30702.72M
Annual income
$22,034,164,620.44/yr
Blended yield
71.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

DTCFF
No analyst data
Altman Z
-31.5
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DTCFF buys
0
PLD buys
0
No recent congressional trades found for DTCFF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDTCFFPLD
Forward yield500.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$61399.52M$5.91M
Annual income after 10y$44,063,578,515.70$4,750,725.19
Total dividends collected$59892.67M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: DTCFF vs PLD ($10,000, DRIP)

YearDTCFF PortfolioDTCFF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$60,700$50,000.00$11,241$540.96+$49.5KDTCFF
2$348,594$283,644.86$13,019$991.13+$335.6KDTCFF
3$1,895,372$1,522,376.89$15,801$1,870.97+$1.88MDTCFF
4$9,763,990$7,735,942.00$20,609$3,701.21+$9.74MDTCFF
5$47,691,977$37,244,507.54$29,919$7,867.97+$47.66MDTCFF
6$221,049,019$170,018,603.23$50,631$18,617.74+$221.00MDTCFF
7$972,993,924$736,471,474.07$105,528$51,352.20+$972.89MDTCFF
8$4,070,762,075$3,029,658,575.98$287,364$174,449.42+$4070.47MDTCFF
9$16,201,818,371$11,846,102,950.68$1,081,760$774,280.77+$16200.74MDTCFF
10$61,399,524,173$44,063,578,515.70$5,908,209$4,750,725.19+$61393.62MDTCFF

DTCFF vs PLD: Complete Analysis 2026

DTCFFStock

Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full DTCFF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this DTCFF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DTCFF vs SCHDDTCFF vs JEPIDTCFF vs ODTCFF vs KODTCFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.